ClinicalTrials.gg
CompletedNCT04332055Updated Mar 27, 2023

RCT Measuring the Effect of the ERVIN Software

An interventional study of ERVIN in Decision Making, Shared, Arthroplasty, Replacement, Knee and Arthroplasty, Replacement, Hip, sponsored by Northern Orthopaedic Division, Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-27.

Sponsored by Northern Orthopaedic Division, Denmark · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The randomised clinical trial investigates the effect of using a clinical decision support system (CDSS) aiming to provide the patients and surgeons with greater transparency concerning the obtainable changes in function and health related quality of life (HRQoL) when patients are to decide if they should undergo hip- or knee replacement surgery.

Read the detailed description

Osteoarthritis (OA) affects 20 % of the adult population in Denmark, and the economic burden to society is estimated to DKK 4.6 billion per year1,2. Symptoms related to evolving OA can usually be effectively managed, and treatment may slow the progression of the disease, however, approximately 10,000 and 8,000 hip and knee replacements, respectively, are performed each year in Denmark due to end-stage OA3-5.

The Danish clinical guidelines for the treatment of OA are compliant with international guidelines and recommend non-pharmacological and complementary pharmacological treatment as first-line treatment modalities3. When non-surgical treatment options become insufficient to relieve pain and improve function, referral to an orthopaedic surgeon for evaluation of whether the patient is eligible for surgery is advised. However, the guidelines do not provide clear guidance on which non-pharmacological treatment(s) or when surgery will be most beneficial for the individual patient, and consequently under- or over-utilisation of healthcare services may occur 3,6 Furthermore, matching patient's expectations with the achievable changes in function level after surgery can be challenging, which might be a contributor to the 20 % proportion of orthopaedic patients that are unsatisfied7,8. It highlights the importance of an enhanced basis for shared decision-making between surgeon and patient, as-well-as bringing focus on each patient's wishes and needs, as these are individual and thus might not be representative of the general population.

Patient-centred care acknowledges the importance of individual values and preferences and empowers patients to take an active part in decisions concerning their health and treatment pathway9. It moves beyond the paternalistic approach to treatment, substituting in its place a partnership-like relation between patient and clinician9,10.

Patient reported outcomes (PRO) have been suggested as a means to improve patient involvement and patient value through a shift in the perception of what constitute "good outcomes", and PRO has on several occasions been shown to be important predictors of clinical outcomes11-13. PRO measures are available for most clinical areas, but implementing a more patient-centred health-care system through PRO is still challenged by i.a. information asymmetry, and lack of aligning expectations12,14.

Denmark has a long tradition of collecting patient-specific data in the health care sector. The challenge today is that the knowledge embedded in these patient-specific health-care data is not utilized to its full potential, neither within nor between the primary and the secondary health care sectors, and, currently, there is a lack of knowledge on how to incorporate data and ePRO (electronic Patient Reported Outcome) to support patients in clinical decision-making.

ERVIN is state of the art for IT systems, which uses artificial intelligence (AI) and real-time patient-specific PRO data to support patients and doctors in clinical decision-making. The system is designed for surgical OA treatment of knee and hip replacement, and can be used to predict outcome scores for the actual choice OA patients face in the patient trajectory; to choose surgery or not.

The clinical and health economic rationale for this study is three-folded: one, to explore if the use of real-time, and predicted ePRO in clinical decision-making impacts patients health; two, to investigate if the use of ERVIN enhances shared decision-making in clinical practice, and third, to investigate if the use of ERVIN is cost-effective.

This study aims to establish the health-related effect and cost-effectiveness of using ERVIN in clinical consultation when the OA patient is referred from the general practitioner to orthopaedic clinic to decide if the patient should have a total hip- or knee replacement.

The increased focus and endorsement of patient-centred care and increased patient involvement in clinical decisions in the Danish health care system is a result of political decisions. The health-related consequences of practising patient centred-care, where patients are more empowered to make decisions are unknown. Furthermore, there is a lack of knowledge of how, and under which conditions, CDDS solutions, like ERVIN, create value in health15,16.

Objective The main objective of this randomised controlled trial is to investigate the health related effects of using ERVIN as a CDSS during consultations, measured by the delta value in Oxford Hip Score (OHS) and Oxford Knee Score (OKS) pre- and post-treatment modalities. Secondary outcomes include investigations of cost-effectiveness and the degree of shared decision-making.

Hypothesis The hypothesis is that the application of ERVIN in consultations, compared with the conventional approach in surgical decision-making concerning hip- or knee replacement, do not lead to any change in OHS or OKS between baseline and at 1-year follow-up.

Methods

Trial design The implementation of ERVIN to enhance patient-centeredness is based on a shift in the government policy for the Danish Health Care system. The new strategy requires increased use of digital solutions in health care and improvement of patient involvement in decisions making17,18. However, the impact on patients' health, when patient involvement is increased by the use of a digital solution like ERVIN is unknown, and for that reason, a non-inferiority design is chosen in the trial.

The trial is a single centre, randomised, controlled trial, which includes two parallel groups. The intervention- and the control group will both have the conventional approach available during the consultation, which includes: A 25-minute consultation in which the surgeon evaluates the need/no need for surgery based on; the patients' subjective description of pains and disabilities, and general health. If available, a description of the aforementioned evaluation criteria from the referring general practitioner will be included in addition to the orthopaedic surgeons' evaluation of relevant x-rays and possible MRI or CT-scans and a physical examination.

The intervention group will have the results from ERVIN as an interface with a graphical presentation of real-time and predicted outcome scores and risk scores.

02

Conditions studied

  • Decision Making, Shared
  • Arthroplasty, Replacement, Knee
  • Arthroplasty, Replacement, Hip
  • Osteoarthritis, Knee
  • Osteoarthritis, Hip
  • Artificial Intelligence
03

In context

Osteoarthritis, Knee

3,292 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's enrollment of 223 is above the median of 68 across 2,714 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Northern Orthopaedic Division, Denmark is the lead sponsor of 61 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients referred from a general practitioner in the North Denmark Region to the orthopaedic clinic at Aalborg University Hospital
  • Patients with painful OA in hip- or knee joint.

Exclusion criteria

Exclusion Criteria:

  • Patients unable to answer the questions in danish
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    ERVIN PLUS

    The doctor and the patient will have access to the ERVIN generated data

    Other: ERVIN

  • No intervention
    ERVIN MINUS

    The doctor and the patient will not have access to the ERVIN generated data

Interventions

  • OtherERVIN

    ERVIN is state of the art for IT systems, which uses artificial intelligence (AI) and real-time patient-specific PRO data to support patients and doctors in clinical decision-making. The system is designed for surgical OA treatment of knee and hip replacement, and can be used to predict outcome scores for the actual choice OA patients face in the patient trajectory; to choose surgery or not.

06

What researchers measure

Primary outcomes

  1. Oxford Hip Score

    The OHS is a short 12-item PRO questionnaire, which is specifically designed and developed to assess the primary outcome in randomised controlled trials with patients undergoing hip or knee replacement surgery. The questionnaires are reproducible, validated and sensitive to clinically important changes24. The primary outcome measure is the delta value in OHS, or OKS measured at baseline, defined as the first consultation in the clinic, and at 1-year follow-up.

    Time frame: 1 year

  2. Oxford Knee Score

    The OKS is a short 12-item PRO questionnaire, which is specifically designed and developed to assess the primary outcome in randomised controlled trials with patients undergoing hip or knee replacement surgery. The questionnaires are reproducible, validated and sensitive to clinically important changes24. The primary outcome measure is the delta value in OHS, or OKS measured at baseline, defined as the first consultation in the clinic, and at 1-year follow-up.

    Time frame: 1 year

Secondary outcomes

  1. HRQoL

    as measures of effect in the economic evaluations. HRQoL is measured by the 15 item questionnaire; EQ-5D-3L

    Time frame: 1 year

  2. SDM

    SDM is measured by two 9-item Shared Decision Making Questionnaires; SDM-Q-9 (patient version), and SDM-Q-Doc (physician version)

    Time frame: 2 hours

07

Study locations

1 site
  • Nanna Kastrup
    Aalborg, Northern Jutland 9000, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Apr 2022, 17 months.

Of 1,111 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 17 months is close to that.

Counting every sponsor, half of 1,251 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2020
First posted
Apr 2, 2020
StartActual
Nov 30, 2020
Primary completionActual
Apr 30, 2022
CompletionActual
Dec 31, 2022
Last update
Mar 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04332055
Lead sponsor
Northern Orthopaedic Division, Denmark
Collaborators
Aalborg University
Responsible party
Sponsor
First posted
Apr 2, 2020
Start date
Nov 30, 2020
Primary completion
Apr 30, 2022
Completion
Dec 31, 2022
Last update
Mar 27, 2023

Study contacts

Nanna Kastrup, MSc
principal investigator · DCHI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion